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ABSTRACT
Radioimmunoconjugates are radioisotope-bound 
monoclonal antibodies that target radiation specifi-
cally to sites of lymphoma involvement. Initial stud-
ies of 131I–tositumomab in non-Hodgkin lymphoma 
(nhl) have suggested benefit in patients with relapsed 
or refractory indolent disease. However, the routine 
adoption of this agent is tempered by concerns about 
associated toxicities and unclear long-term benefit. 
Based on a comprehensive search for studies on 
131I–tositumomab use in lymphoma, this systematic 
review summarizes and evaluates the evidence on
•  the benefits and risks of this novel therapy,
•  the predictors for response and toxicity, and
•  the role of dosimetry and imaging studies be-
fore treatment.
We identified 18 trials investigating the use of 
131I–tositumomab for the treatment of adult patients 
with nhl. In trials of patients with relapsed or refrac-
tory indolent nhl, overall response rates ranged from 
67% to 83%. In patients with follicular nhl refractory 
to the monoclonal antibody rituximab, response rates 
remained high (65%–72%). However, in rituximab-
naïve patients with relapsed or refractory indolent or 
transformed nhl, improvements in time to progres-
sion or survival have not been clearly established. 
131I–Tositumomab is an active agent in relapsed and 
refractory non-Hodgkin lymphoma that should be 
considered in selected patients.
KEY WORDS
131I–Tositumomab, Bexxar, indolent lymphoma, 
systematic review
1.  INTRODUCTION
Non-Hodgkin lymphomas (nhls) constitute a het-
erogeneous group of malignancies with variable 
presentations that range from indolent to aggressive 1. 
Patients with follicular and other indolent lymphomas 
can sustain prolonged remission periods, but they 
eventually relapse and require subsequent courses of 
therapy that lead to fewer and shorter remissions 2. 
Novel treatment options are necessary to improve 
the natural history of this condition. Rituximab is a 
chimeric monoclonal antibody directed against the 
CD20 surface antigen found on most B-cell lympho-
mas 3. Although rituximab represents an important 
advance in indolent disease because of its efficacy, 
short duration of therapy, and acceptable toxicity 
profile 4, relapse remains inevitable. Therapies that are 
more effective are thus needed for patients who are 
refractory to or who relapse after currently available 
treatments, including rituximab.
Radioimmunoconjugates are monoclonal antibod-
ies bound to radioisotopes, and this emerging class of 
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agents has activity in lymphoma. These agents allow 
for the delivery of targeted radiation therapy with 
the binding of the monoclonal antibody to antigens 
on the surface of malignant cells. 131I–Tositumomab 
(Bexxar: Corixa Corporation, South San Francisco, 
CA, and GlaxoSmithKline, Philadelphia, PA, U.S.A.) 
is a radioimmunoconjugate consisting of an anti-
CD20 murine monoclonal antibody (tositumomab) 
covalently bound to the gamma-emitting radioactive 
isotope 131I 5,6. Initial studies have reported on the use 
of 131I–tositumomab in patients with refractory or re-
lapsed low-grade, follicular, or transformed lymphoma. 
Further research is exploring the role of this compound 
in other settings, including in patients with aggressive-
histology lymphomas and in the setting of stem-cell 
transplantation. However, the routine adoption of this 
agent is tempered by concerns about increased costs, 
complex dosimetry requirements, and possible toxici-
ties. With the recent availability of radioimmunoconju-
gates, a careful review of the risks and benefits of such 
therapy is warranted. The aim of the present systematic 
review is to address the following questions in patients 
with lymphoma of any type or stage:
•  What are the benefits associated with treatment 
with 131I–tositumomab?
•  What are the toxicities associated with the use of 
131I–tositumomab?
•  Which patients are more or less likely to benefit 
from treatment with 131I–tositumomab?
•  Is imaging or dosimetry required for therapy to 
be safe and effective?
2.  MATERIALS AND METHODS
The methodology guiding this systematic review was 
developed by the Cancer Care Ontario (cco) Program 
in Evidence-Based Care (pebc) according to the prac-
tice guidelines development cycle 7. Members of the 
pebc Hematology Disease Site Group (dsg) selected, 
reviewed, and interpreted the evidence. The Hematol-
ogy dsg has 25 members, including hematologists, 
medical and radiation oncologists, an epidemiologist, 
and two lay representatives.
2.1  Literature Search
We searched the medline (1966 to July 2005), embase 
(1980 to July 2005), and Cochrane Library (2005, Is-
sue 3) databases using the search strategy shown in 
Table i. In addition, we searched the conference proceed-
ings of the American Society of Hematology (ash) for 
2000 to 2004 and those of the American Society of Clini-
cal Oncology (asco) for 2000 to 2005. Reference lists of 
relevant trials and reviews were searched for additional 
publications. In addition, the authors searched their per-
sonal files. The Canadian Medical Association Infobase 
(mdm.ca/cpgsnew/cpgs/index.asp), the National Guide-
lines Clearinghouse (www.guideline.gov/index.asp), 
and the U.K. National Institute for Health and Clinical 
Excellence (www.nice.org.uk/) were also searched for 
existing evidence-based practice guidelines.
2.2  Inclusion Criteria
Randomized controlled trials, other comparative tri-
als, prospective single-arm trials, systematic reviews 
(with or without meta-analyses), and evidence-based 
practice guidelines were considered for this review of 
the evidence if they met the following criteria:
•  Study of adult patients with lymphoma of any type, 
at any stage, and for any performance status
•  131I–Tositumomab studied as a single agent or in 
combination with other regimens
•  Results reported for one or more of the following 
outcomes: survival, quality of life (qol), time to 
progression (ttp), response duration, response rate, 
adverse effects, tumour dosimetry or imaging
•  Report published in English
table i  Literature search strategy
Step Search term
1 zevalin.mp.
2 ibritumomab tiuxetan.mp.
3 anti-CD20.mp.a
4 antiCD20.mp.a
5 antiCD-20.mp.a
6 idec-y2b8.mp.
7 idecy2b8.mp.
8 idec-2b8.mp.
9 idec2b8.mp.
10 idec-In2b8.mp.
11 idecIn2b8.mp.
12 idec-129.mp.
13 idec129.mp.
14 or/1–13
15 lymphoma.mp.
16 exp lymphoma/
17 exp lymphoma, large-cell/b
18 or/15–17
19 14 and 18
20 limit 19 to human
21 limit 20 to English language
22 comment.pt.
23 letter.pt.
24 editorial.pt.
25 or/22–24
26 21 not 25c
27 20 not 21
28 27 not 25d
a  Included in the original literature search (July 2003).
b  Included in the May 2004 literature search.
c  Results for citations in the English language.34
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Letters, comments, and editorial publications 
were excluded. Conference abstracts that preceded 
full-paper final results were not included; however, 
abstracts that provided updated results or novel data 
were included for further data abstraction.
2.3  Data Extraction and Interpretative Summary
Relevant articles and abstracts were selected in an 
unblinded manner independently by two members of 
the Hematology dsg. Data were extracted and sum-
marized to address the following questions regarding 
adult patients with lymphoma of any type, at any 
stage, and for any performance status:
•  Is 131I–tositumomab effective in improving surviv-
al, qol, ttp, response duration, or response rate?
•  What are the toxicities associated with the use of 
131I–tositumomab?
•  Which patients are more or less likely to benefit 
from treatment with 131I–tositumomab?
•  Is imaging or dosimetry required for therapy to 
be safe and effective?
The analysis of the data uses descriptive statis-
tics. Categorical variables are reported as numbers 
and proportions, and continuous data are reported as 
means and standard deviations. The heterogeneity 
among studies precluded any pooling of results using 
formal meta-analytic techniques.
3.  RESULTS
We identified 255 citations in the literature searches 
of medline, embase, and the Cochrane Library, in-
cluding twenty-one full publications of eleven trials. 
Eleven abstracts of seven trials were identified from 
the conference proceedings of ash and asco. One ad-
ditional abstract was identified that provided qol data 
that were not reported in the relevant full publication. 
Only the most recent abstract or full publication was 
referenced for each trial, except where additional data 
were available in previous publications (Table iia).
In total, this systematic review includes eighteen 
trials investigating the use of 131I–tositumomab for the 
treatment of adult patients with nhl. No systematic 
reviews, meta-analyses, or evidence-based practice 
guidelines were identified. We divided the trials into 
two categories based on patient treatment history: pre-
viously untreated 25,27,29,31,35 and previously treated pa-
tients with nhl. The “previously treated” category was 
further divided into randomized 22 and single-arm trials 
of 131I–tositumomab. The single-arm trials included 
reports of patients with disease relapsed or refractory 
to chemotherapy without prior rituximab 5,8,11,12,19,28; 
disease relapsed or refractory to rituximab alone 34,39; 
disease treated with 131I–tositumomab conditioning 
a    Also see Appendix a, which describes an update to the origi-
nal search and the articles located as a result.
for autologous stem-cell transplantation (asct) 17,40; 
and disease treated with 131I–tositumomab in alterna-
tive regimens or alternative populations of previously 
treated patients 23,32.
3.1  Patients with Previously Treated NHL
3.1.1  Study Quality
Only one of the thirteen trials of 131I–tositumomab in 
patients with previously treated nhl was a randomized 
table ii  Primary and additional publications of trials included in 
this systematic review
Primary publication Publications with  
additional information
Press et al., 1993 8 Liu et al., 1998 9
Gopal et al., 2003 10
Press et al., 1995 11 Liu et al., 1998 9
Gopal et al., 2003 10
Kaminski et al., 2000 12 Kaminski et al., 1993 13
Kaminski et al., 1996 14
Wahl et al., 1998 15
Bennet et al., 2005 16
Press et al., 2000 17 Gopal et al., 2002 18
Vose et al., 2000 19 Kaminski et al., 2001 20 
(abstract)
Sgouros et al., 2003 21
Bennet et al., 2005 16
Kaminski et al., 2001 5 Kaminski et al., 2001 20 
(abstract)
Sgouros et al., 2003 21
Bennet et al., 2005 16
Davis et al., 2003 22 (abstract) Bennet et al., 2005 16
Kaminski et al., 2003 23 (abstract) Kaminski et al., 2005 24,a
Press et al., 2003 25 Press et al., 2006 26,a
Zelenetz et al., 2003 27 (abstract) None
Davies et al., 2004 28 None
Leonard et al., 2004 29 (abstract) Leonard et al., 2005 30,a
Link et al., 2004 31 (abstract) None
Mones et al., 2004 32 (abstract) Mones et al., 2007 33,a
Horning et al., 2005 34 Bennet et al., 2005 16
Kaminski et al., 2005 35 Koral et al., 2000 21
Koral et al., 2000 36
Koral et al., 2002 37
Koral et al., 2003 38
Bennet et al., 2005 16
Nair et al., 2005 39 (abstract) None
Vose et al., 2005 40 None
a  See Appendix a for details regarding this publication.35
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controlled trial 22. That trial has been published in 
abstract form only, and therefore little information 
regarding study quality was reported. However, the 
authors did report that the trial was multicentred and 
open-label. The 78 study patients were randomized 
either to  131I–tositumomab or to unlabelled tosi-
tumomab and were followed for a median of 42.6 
months. No sample-size calculation was provided.
One single-arm trial, reported as a full publication 
by Kaminski et al. 5, compared each patient’s duration 
of response after 131I–tositumomab with the duration 
of response to their last qualifying chemotherapy regi-
men (“paired control”). The remaining studies were 
single-arm noncomparative phase i or ii trials. Eight 
of those trials 5,8,11,12,17,19,22,28,34,40 have been fully 
published, with sample sizes ranging from 11 patients 
to 60 patients. The remaining three trials 23,32,39 have 
been published in abstract form only, with sample 
sizes ranging from 11 patients to 32 patients. Eight 
of twelve single-arm trials reported median follow-up 
times that ranged from 12 months 11 to 39 months 34.
3.1.2  Study Characteristics
Table iii presents study and patient characteristics for 
the trials of 131I–tositumomab in patients with previ-
ously treated nhl. The randomized trial reported by 
Davis et al. 22 included patients with CD20+ nhl that 
was relapsed or refractory (defined as progression 
within 1 year of treatment) to a regimen containing 
either an anthracycline, an anthracenedione, or an al-
kylating agent. Patients were randomized to either 131I–
tositumomab (n = 42) or to unlabelled tositumomab 
(n = 36). Patients who did not respond to unlabelled 
tositumomab could cross over to the 131I–tositumomab 
arm if they did not have a human anti-mouse antibody 
(hama) response. The authors did not report the doses 
given to patients in either arm. Patient characteristics 
were well matched between the two treatment arms.
Six of the single-arm trials enrolled patients with 
nhl that was relapsed or refractory to chemotherapy 
without rituximab: one phase i dose-escalation trial 8, 
one phase i/ii dose-escalation trial 12, and four phase ii 
trials 5,11,19,28. One of the phase ii trials used each 
patient as a self paired control for comparing the 
duration of response to 131I–tositumomab with the 
duration of response in the patient’s last qualifying 
chemotherapy regimen 5. The phase i trial reported 
by Press et al. 8 was a dose-escalation study that 
provided separate outcomes data for the 12 patients 
who received therapeutic doses of 131I–tositumomab. 
Gopal et al. 10 reported a study that compared patients 
in sequential trials reported by Press et al. 22,27 (treat-
ment group, n = 27) with a historical control group of 
patients who received conventional high-dose therapy 
and asct (control group, n = 98).
Two single-arm phase ii trials enrolled patients 
with nhl relapsed or refractory to rituximab, with 
or without chemotherapy. The first trial, reported by 
Horning et al. 34 included patients who were relapsed 
or refractory to rituximab. Nair et al. 39 reported a trial 
that enrolled patients with CD20+ nhl refractory to 
chemotherapy and rituximab.
Two single-arm phase i dose escalation trials 
treated patients who had chemotherapy-resistant nhl 
with a regimen including 131I–tositumomab condi-
tioning for asct 17,40.
Mones et al. 32 reported the results of a phase i trial 
that enrolled patients who had relapsed or refractory 
low-grade nhl and more than 25% bone marrow in-
volvement. The first cohort of patients received 131I–
tositumomab at a total body dose of 45 cGy, with incre-
mental increases of 10 cGy for subsequent cohorts.
Four of the single-arm trials reported subgroup 
data for patients with transformed nhl 5,12,19,28. Three 
additional trials 17,23,34 reported that 12%–23% of 
enrolled patients had transformed nhl, but they did 
not provide outcomes data for that subgroup of pa-
tients. An integrated pooled analysis of five of these 
studies 5,12,19,28,34 reported outcomes unique to this 
subgroup of patients 43,44,45. In this population of 71 
evaluable patients with transformed nhl, the median 
time from diagnosis to therapy was 74 months, and the 
median time from transformation was 21 months 45.
3.1.3  Response Rate
In previously treated patients, objective response rates 
ranged from 85% to 100%, with complete response 
(cr) rates of 20%–84% 5,8,11,12,17,19,22,23,28,32,34,39,40 
(Table iv). In the randomized trial 22, a statistically 
significant difference was observed in objective re-
sponse between the 131I–tositumomab group and the 
unlabelled tositumomab group (55% vs. 19%), with 
cr rates of 33% versus 8% (statistical significance not 
reported). Response rates in rituximab-naïve patients 
ranged from 57% 19 to 100% 8 with cr rates from 
20% 5 to 83% 8. Response to 131I–tositumomab ap-
peared to compare favourably with the response to the 
preceding line of therapy (chemotherapy alone) 5. For 
patients that had relapsed after or were refractory to 
rituximab (with or without chemotherapy), response 
rates were 65% 34 and 72% 39 respectively.
The response rates were 65% 40 and 87% 17 in the 
trials that treated patients with 131I–tositumomab as 
part of multi-agent chemotherapy conditioning for 
asct, with cr rates of 57% 40 and 77% 17.
One trial treated patients with more than 25% 
bone marrow involvement (a relative contraindica-
tion to the use of 131I–tositumomab) and observed an 
objective response rate of 18% in 11 patients 32.
A pooled analysis of five trials 43,44,45 provided 
response data for the subgroup of patients with trans-
formed nhl. A pooled response rate of 39% with a cr 
rate of 25% was reported.
3.1.4  Time to Progression
In previously treated patients, ttp data were reported 
for ten trials (Table iv). One randomized trial 22 report-
ed that median ttp was longer in the 131I–tositumomab 36
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i
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arm as compared with the unlabelled tositumomab 
arm (6.3 months vs. 5.5 months, p = 0.031). Six sin-
gle-arm trials of patients who were previously treated 
with chemotherapy or rituximab, or both 5,12,19,28,34, or 
with prior 131I–tositumomab 23, reported median ttp 
ranges from 8.4 months to 12 months. One trial re-
ported a 1-year progression-free survival of 66% 11.
3.1.5  Response Duration
Data on response duration in previously treated 
patients were reported in eight trials (Table iv). In 
the randomized trial 22, median response duration 
was not reached in the 131I–tositumomab arm; it was 
28.1 months in the unlabelled tositumomab arm (p = 
not reported). In previously treated patients who had 
not received rituximab, median response duration 
ranged from 6.5 months 5 to 15 months 6. In the trial 
that compared 131I–tositumomab response with that 
attained for last chemotherapy regimen in the same 
patients 5, 17 of 60 patients achieved a response du-
ration after 131I–tositumomab that was equivalent to 
their most recent lymphoma treatment; 53% achieved 
a longer response duration after 131I–tositumomab 
(p < 0.001). In individuals with transformed nhl, the 
pooled analysis of five trials documented a median 
response duration of 20 months. In addition, of the 
25% of individuals who attained a cr, median re-
sponse duration reached 36.5 months 45.
3.1.6  Survival
In the trials that included patients who had  nhl 
relapsed or refractory to chemotherapy without 
rituximab, the median os ranged from 21 months 8 to 
41 months 12, with two trials reporting that the median 
os was not reached at 12 months 11 and 36 months 28 
of follow-up (Table iv). In patients with disease that 
was relapsed or refractory to rituximab, median os had 
not yet been reached at 39 months 34. In patients who 
received 131I–tositumomab conditioning for asct, one 
trial reported a median os of 36 months 40, and another 
trial reported a 2-year os of 83% 17.
3.1.7  Quality of Life
Only one of the thirteen trials of 131I–tositumomab in 
previously treated patients reported data on qol 20. The 
European Organization for Research and Treatment of 
Cancer quality of life questionnaire was administered 
to the patient cohort receiving 131I–tositumomab after 
previous lymphoma treatment without rituximab. The 
authors reported that the scales for emotional func-
tion, social function, global health status, nausea/
vomiting, and appetite loss demonstrated statistically 
significant improvements at one or more time points; 
however, no data or p values were reported.
3.1.8  Adverse Events
The randomized trial 22 comparing 131I–tositumomab 
with unlabelled tositumomab reported comparative 
grade 4 hematologic toxicities. Thrombocytopenia 
(12% vs. 0%), neutropenia (17% vs. 3%), and ane-
mia (5% vs. 0%) occurred more frequently with 
radioimmunotherapy, although whether these differ-
ences were statistically significant was not reported 
(Table v).
The rates of adverse events were similar in 
patients who had 34,39 and who had not 5,8,11,12,19,28 
received prior rituximab. Myelosuppression was 
common, but tended to be delayed in onset, with 
cytopenia nadirs occurring 7–9 weeks after treat-
ment. Eight trials reported on the rate of infection, 
with grades 1–4 infections occurring in 21%–55% of 
patients 5,8,11,12,19,23,34. The rate of hospitalization from 
infection was reported in three trials and ranged from 
2% to 15% 5,23,28. Non-hematologic toxicity was com-
mon (reported in 80% of patients), generally mild, 
and related to drug infusion. Grades 1 and 2 adverse 
events occurred in a high proportion of patients in all 
trials, with the most common events being headache, 
fever, chills, infection, nausea, and vomiting. Table v 
summarizes these adverse events.
The rate of  hama response was reported in 
ten single-arm trials, occurring in 0%–35% of pa-
tients 5,8,11,12,19,17,23,28,34,40. Hypothyroidism was 
reported in six trials, and for the 131I–tositumomab 
arm of the randomized trial, it occurred in 7%–42% 
of patients 5,8,11,12,22,23,34.
The rate of myelodysplastic syndrome (mds) 
was reported in eight trials and ranged from 0% to 
9% 5,8,9,11,12,23,28,34,40. One study that included patients 
from six trials and an expanded access program re-
ported on mds and acute myeloid leukemia (aml) in 
patients treated with 131I–tositumomab 16: 35 of 1071 
patients developed mds or aml for an annualized in-
cidence of 1.4% per year (95% confidence interval: 
1.0% to 2.0% per year).
3.1.9  Prognostic Factors
Predictors for overall response included tumour bur-
den below 500 g 5, grade i or ii disease and tumour 
size 7 cm or less 34, lymph node diameter less than 
5 cm 28, low-grade nhl 5,12, bone marrow involve-
ment 5, fewer than 4 prior chemotherapy regimens 5, 
and no prior radiotherapy 5. The prior use of 2 or more 
chemotherapy regimens was associated with a shorter 
duration of remission 28.
3.1.10  Dosimetry and Imaging
Dosimetry is a method of estimating the dose of 
radiation administered to specific organs. Imaging 
refers to the evaluation of gamma images to ensure 
that drug biodistribution is appropriate 46. Dosimetry 
is required to determine the dose of 131I–tositumomab 
to be administered 21,47, and it was used in all trials 
in patients with previously treated nhl. No dose–
response relationship was noted between absorbed 
dose and tumour response 21. Also, no correlation 
was observed between total body tumour burden and 
objective response or toxicity 21.39
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3.2  Patients with Previously Untreated NHL
3.2.1  Study Quality
No randomized controlled trials of 131I–tositumomab in 
patients with previously untreated nhl were identified. 
All of the five studies located were single-arm noncom-
parative phase ii trials with sample sizes ranging from 
13 patients to 90 patients 25,27,29,31,35. Median follow-up 
ranged from 11 months to 61.2 months.
3.2.2  Study Characteristics
Table vi details the study and patient characteristics 
of trials of 131I–tositumomab in patients with previ-
ously untreated nhl.
3.2.3  Response Rate
Table vii presents response data for the five trials of 
131I–tositumomab in the previously untreated patient 
population. In the four trials of 131I–tositumomab 
alone 35 or after chemotherapy 25,29,31, objective 
response rates ranged from 90% to 100%, with 
cr rates from 67% to 83%. In a trial of sequential 
therapy with 131I–tositumomab followed by chop 
(cyclophosphamide, doxorubicin, vincristine, pred-
nisone) chemotherapy (×6 cycles) in patients with 
mantle-cell nhl, the response rate was 83% after 
131I–tositumomab (cr rate: 50%) and by intention-to-
treat analysis, the response rate was 75% after chop 
(all of which were crs) 27.
3.2.4  Time to Progression
Table vii presents data on ttp. One trial reported a me-
dian ttp of 73.2 months 35 and another reported a 2-year 
progression-free survival of 81% 25. Median ttp had not 
yet been reached in two other trials in which the median 
follow-up periods were 28 and 53 months 29,31.
3.2.5  Response Duration
Only one trial 27 reported median response dura-
tion, which had not yet been reached after a median 
follow-up of 11 months (Table vii). Among the subset 
of patients who experienced a cr 35, 40 of 57 had expe-
rienced an ongoing cr for 4.3–7.7 years. A third trial 29 
reported that the median duration of cr was not reached 
after a median follow-up of 52.8 months, with 72% of 
29 patients with a cr remaining in remission.
3.2.6  Survival
Two trials reported survival data for previously un-
treated patients (Table vii). One reported a 5-year os of 
89% 35, and another reported a 2-year os of 97% 25.
3.2.7  Quality of Life
None of the trials of patients with previously untreated 
nhl reported data on qol.
3.2.8  Adverse Events
Table viii summarizes adverse events in the previously 
untreated population. Grades 3 and 4 thrombocy-
topenia ranged from 11% to 29%; neutropenia, from 
13% to 34%; and anemia, from 0% to 3% 25,29,31,35. 
Grade 3 infection occurred in 2% of patients 25, and 
febrile neutropenia was reported as 0% in one trial 35 
and 42% in another 27. One trial reported a 0% rate 
of hospitalization as a result of infection 35; no other 
trials reported hospitalization data.
Elevated thyroid-stimulating hormone occurred 
in 7%–12% of patients 25,29,35, and hama occurred 
table vi  Single-arm trials of 131I–tositumomab (131itb) in patients with previously untreated non-Hodgkin lymphoma (nhl): study characteristics
Reference Patient characteristics Intervention Pts
(n)a
Press et al., 2003 25 Previously untreated CD20+ stage ii-iv follicular nhl chop (cyclophosphamide 750 mg/m2 day 1, plus 90
doxorubicin 50 mg/m2 day 1, plus
vincristine 1.4 mg/m2 day 1, plus
prednisone 100 mg days 1–5)
every 21 days for 6 cycles,
followed by 131itb (total body dose: 75 cGy)
Zelenetz et al., 2003 27 Previously untreated mantle-cell lymphoma 131itb (total body dose: nr), 13
(abstract) followed 13–16 weeks later by chopb
Leonard et al., 2004 29 Previously untreated advanced low-grade nhl Fludarabine 25 mg/m2 daily for 5 days, 38
(abstract) every 5 weeks for 3 cycles,
followed by 131itb (total body dose: 75 cGy)
Link et al., 2004 31
(abstract) Previously untreated follicular nhl cvp (cyclophosphamide 400 mg/m2 days 1–5, plus 30
vincristine 1.4 mg/m2 day 1, plus
prednisone 100 mg/m2 days 1–5)
every 21 days for 6 cycles,
followed by 131itb (total body dose: 75 cGy)
Kaminski et al., 2005 35 Previously untreated advanced-stage follicular nhl 131itb (total body dose: 75 cGy) 76
a  Number enrolled and eligible.
b  Standard chop, but with a cyclophosphamide dose of 1000 mg/m2.
Pts = patients; nr = not reported.41
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table vii  Single-arm trials of 131I–tositumomab (131itb) in patients with previously untreated non-Hodgkin lymphoma: response and survival
Reference Intervention Pts Or Cr Median results (months) for
(n)a (%) (%) ttp Response Os Follow-
duration up
Press et al., 2003 25 chop followed by 131itb 90 90 67 Not yet reached nr Not yet reached 27.6
(total body dose: 75 cGy)
Zelenetz, 2003 27 131itb (total body dose: nr) 12b 75 75 nr Not yet reached nr 11
(abstract) followed by chop
Leonard et al., 2004 29 Fludarabine, followed by 131itb 35c 100 83 Not yet reached nr nr 52.8
(abstract) (total body dose: 75 cGy)
Link et al., 2004 31 cvp followed by 131itb 30 100 80 Not yet reached nr nr 27.6
(abstract) (total body dose: 75 cGy)
Kaminski et al., 2005 35 131itb (total body dose: 75 cGy) 76 95 75 73.2 nr Not yet reached 61.2
a  Number included in the analysis.
b  Of 13 enrolled patients, 1 did not receive treatment with 131itb and was not included in the analysis of the data.
c  Of 38 enrolled patients, 3 did not receive treatment with 131itb and were not included in the analysis of the data.
Pts = patients; or = complete response, unconfirmed complete response, and partial response; cr = complete response and unconfirmed 
complete response; ttp = time to progression; os = overall survival; chop = cyclophosphamide, doxorubicin, vincristine, prednisone; 
nr = not reported; cvp = cyclophosphamide, vincristine, and prednisone.
table viii Single-arm trials of 131I–tositumomab (131itb) in patients with previously Untreated non-Hodgkin lymphoma: adverse events
Reference Intervention Pts Thrombo- Neutro- Anemia Infection Febrile Human
(n)a cytopenia penia (grades (grades neutron- anti-mouse
(grades 
3–4)
(grades  
3–4)
3–4)  
(%)
1–4)  
(%)
penia 
(%)
antibody 
(%)
(%) (%)
Press et al., 2003 25 chop followed by 131itb 82b 11 13 2 2 (grade 3) nr nr
(total body dose: 75 cGy)
Zelenetz et al., 2003 27 131itb (total body dose: nr) 12c nr nr nr nr 42 16
(abstract) followed by chopa
Leonard et al., 2004 29 Fludarabine followed by 131itb 35d 29 (grade 4) 34 (grade 4) 3 (grade 4) nr nr 6
(abstract) (total body dose: 75 cGy)
Link et al., 2004 31 cvp followed by 131itb 30 23 (grade 4) 33 (grade 4) nr nr nr 0
(abstract) (total body dose: 75 cGy)
Kaminski et al., 2005 35 131itb (total body dose: 75 cGy) 76 17 34 0 nr 0 63
a  Number included in analysis.
b  Of 90 enrolled patients, 9 were not evaluable for toxicity.
c  Of 13 enrolled patients, 1 did not receive treatment with 131itb and was not included in the analysis of the data.
d  Of 38 enrolled patients, 3 did not receive treatment with 131itb and were not included in the analysis of the data.
Pts = patients; chop = cyclophosphamide, doxorubicin, vincristine, prednisone; nr = not reported; cvp = cyclophosphamide, vincristine, 
and prednisone.
in 0%–63% 27,29,31,35, with mds or aml occurring in 
0%–3% of patients 25,31,35.
3.2.9  Prognostic Factors
One trial reported on predictive factors 35. Nodal 
diameters of 5 cm or more were associated with 
lower response rates, and bone marrow involve-
ment was also associated with lower response rates. 
Only bone marrow involvement had a significant 
effect on progression-free survival, predicting for 
a worse outcome.
3.2.10  Dosimetry and Imaging
All of the trials that enrolled patients with previously 
untreated nhl used dosimetry and imaging in the trial 
protocol. Dosimetry is part of the 131I–tositumomab regi-
men. One publication 38 provided updated data on patients 
in three other publications 36,37,47 and on an additional 
19 patients. The authors reported that, for patients with 
previously untreated follicular nhl who received 131I–
tositumomab, those with tumours receiving the highest 
radiation doses were more likely to achieve a cr; how-
ever, that association was not statistically significant.42
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4.  DISCUSSION
The development of the monoclonal antibody ritux-
imab has significantly advanced the treatment of 
lymphomas that express the target CD20 antigen. 
The anti-lymphoma benefit of rituximab is likely 
multifactorial, including antibody- and complement-
dependent cellular cytotoxicity mechanisms 4. In 
addition to these immunobiologic effects, radioim-
munoconjugates have the potential to direct radia-
tion exclusively to the site of disease involvement, 
minimizing exposure to uninvolved organs. The 
adoption of these agents will depend on whether the 
incremental anti-lymphoma activity can translate into 
improved long-term outcomes without undue toxicity.
Patients with indolent lymphoma are treated 
episodically with chemotherapy, immunotherapy, 
or radiation often over a period of many years, 
sometimes decades. Therapy is initially highly effec-
tive in palliating symptoms and relieving potentially 
life-threatening complications, but it is not curative. 
Over time, response rates diminish and become less 
durable. The outcome for patients who are refractory 
to rituximab is particularly poor, and few alternative 
treatment options remain. In this context of heavily 
pretreated disease, the evidence supports the use of 
131I–tositumomab. 131I–Tositumomab demonstrated 
significant anti-lymphoma activity in six single-arm 
trials in patients with nhl relapsed or refractory to che-
motherapy without rituximab and in two single-arm 
phase ii trials in patients with nhl relapsed or refrac-
tory to rituximab with or without chemotherapy.
For most of this heavily pretreated patient popu-
lation, therapeutic options have been exhausted. A 
standard comparison therefore does not exist. 
However, one trial used each patient as a paired self 
control for comparing duration of response with the 
patient’s last qualifying chemotherapy regimen 5. 
That trial reported a significant difference in objective 
response (65% with 131I–tositumomab vs. 28% with 
last chemotherapy), and 53% of patients had a longer 
response duration after 131I–tositumomab than after 
their most recent chemotherapy. This longer response 
may represent a beneficial effect on the natural history 
of the disease because, typically, a lower response rate 
and shorter duration of response are observed with 
each successive treatment. In addition, a proportion 
of responders had very long durable remissions. For 
patients with a cr, median duration of response was 
47.2 months as compared with only 4.8 months for 
their last qualifying chemotherapy. Given the limited 
available treatment options for pretreated patients, the 
use of 131I–tositumomab may offer benefit when other 
treatments (including rituximab) have failed.
The role of 131I–tositumomab in individuals with 
transformed low-grade nhl is also of interest, given 
the poor prognosis associated with currently avail-
able therapies. An integrated analysis of patients with 
transformation across five trials documented moderate 
response rates and a median response duration of 20 
months, results that were commensurate with the 
heavily pretreated low-grade population 43. However, 
this small and selected population of patients with an 
extended time from transformation until treatment 
with 131I–tositumomab may not be reflective of all 
patients with transformed nhl 45, and further prospec-
tive data for this unique presentation are warranted. 
The data do not currently identify whether there is 
a differential benefit between the various indolent 
histologies (follicular vs. non-follicular) enrolled in 
these pivotal trials.
The data supporting the use of 131I–tositumomab in 
previously untreated patients with nhl are limited. No 
randomized controlled trials have compared 131I–tositu-
momab with standard therapy, and therefore the use of 
131I–tositumomab in this patient population should be 
reserved until evidence becomes available supporting 
improved clinical outcomes with 131I–tositumomab as 
compared with current standard therapies.
The evidence for 131I–tositumomab as part of a 
conditioning regimen before asct is limited to two 
single-arm trials 17,40. Although encouraging, the 
limited data preclude any clear conclusions of benefit 
in that setting.
The toxicities of  131I–tositumomab are pre-
dictable. The main toxicity is hematologic, with 
delayed-onset cytopenias whose nadirs occur at 
7–9 weeks from treatment. Particular attention to 
severe myelosuppression is warranted for patients 
with known bone marrow involvement and throm-
bocytopenia preceding therapy. Dose reductions are 
required if platelets reach 100–150×109/L, and the 
drug should not be administered if platelets are less 
than 100×109/L, absolute neutrophil count is less than 
1.5×109/L, or bone marrow involvement is greater 
than 25%. The annualized incidence of mds and aml in 
patients with previously treated nhl is 1.4% per year 
and would be considered acceptable in this group of 
patients who have often received prior leukemogenic 
anti-lymphoma therapies such as alkylating agents. 
The incidence of hama varied from 0% to 35% and 
is of questionable clinical significance.
The evidence has highlighted a number of predic-
tors for response to radioimmunotherapy. Common 
predictors for response include indolent-histology 
disease (compared with transformed histology), non-
bulky disease, and fewer prior therapies. However, 
these results should be considered hypothesis-gener-
ating at this time, given the limited sample sizes on 
which the subgroup analyses were based.
The final question that guided this review was 
the role of dosimetry in establishing the safety and 
efficacy of 131I–tositumomab. Although dosimetric 
findings did not correlate with tumour response, 
dosimetry was performed in all clinical studies in-
volving this agent and is currently mandated in North 
American and European jurisdictions to determine the 
patient-specific therapeutic dose. Although there may 43
Current OnCOlOgy—VOlume 16, number 5
CHEUNG et al.
be logistic barriers to the performance of dosimetry, 
especially in smaller centres of practice, these limita-
tions are out of the scope of the present review.
Currently, no comparative data addressing the 
use of one radioimmunoconjugate over another are 
available. Another radiolabelled anti-CD20 antibody, 
90Y-ibritumomab tiuxetan (Zevalin: idec Pharmaceu-
ticals, San Diego, CA, U.S.A.), is being studied pre-
dominantly in indolent and transformed lymphoma. 
Important differences in radiation characteristics and 
dosimetry requirements may limit the class generaliz-
ability of these antibodies.
The strengths of the present review include the 
use of validated methods for the performance of sys-
tematic reviews, extension of the literature search to 
include preliminary abstract data to minimize publica-
tion bias, and objective data abstraction according to 
predefined outcome questions. However, the review 
does have limitations. For most of the trials, we did 
not formally appraise study quality because they were 
phase ii studies and several were reported only in 
abstract form. This lack of appraisal limited the dis-
crimination and utility of any methodologic grading 
scores. Also, the variability of the data precluded any 
pooling of results or use of meta-analytic summary 
techniques. We appreciate that the data come largely 
from single-arm studies and that the results are subject 
to selection bias; however, we have tempered our con-
clusions regarding this agent to reflect the currently 
available evidence. Finally, we acknowledge that the 
evidence regarding the role of 131I–tositumomab will 
continue to mature and evolve beyond this original 
systematic review and summary document. A current 
listing of phase iii trials is provided in Table ix, and 
we invite practitioners and patients to review the Web 
site of the pebc (www.cancercare.on.ca/cms/One.aspx
?portalId=1377&pageId=10269) to remain abreast of 
the update process mandated for these guidelines.
Despite limitations, the data suggest a role for 
131I–tositumomab in selected patients with nhl. The 
current evidence supports a role in the management 
of indolent lymphoma refractory to prior therapy that 
includes rituximab with or without chemotherapy. The 
precise role of 131I–tositumomab within the lymphoma 
armamentarium will undoubtedly continue to evolve.
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table ix  Ongoing comparative or phase iii trials
Protocol ID Title and details of trial
swog S0016 Phase iii Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (chop) with Either 
Rituximab or Iodine 131I–Tositumomab (Monoclonal Antibody Anti-B1) in Patients with Newly Diagnosed Fol-
licular Non-Hodgkin’s Lymphoma
Outcomes: Progression-free survival, overall survival, response, toxicity
Projected accrual: 500 patients
Status: Study is ongoing, but not recruiting participants
Notes: A chop-only arm closed to recruitment on December 15, 2002
Summary last modified: April 14, 2009
Accessed: May 10, 2009
Available at: www.clinicaltrials.gov/ct2/show/NCT00006721
NCT00006721
calgb 50102
bmt CTN0401 Phase iii Rituxan/beam vs. Bexxar/beam with Autologous Hematopoietic Stem Cell Transplantation (asct) for 
Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin’s Lymphoma
Outcomes: Progression-free survival, overall survival, response, toxicity
Projected accrual: 224 patients
Status: Currently recruiting
Summary last modified: April 8, 2009
Accessed: May 10, 2009
Available at: www.clinicaltrials.gov/ct2/show/NCT00329030
NCT00329030
CCBX001-053 A Comparative Study of Iodine I-131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Thera-
peutic Regimen
Status: Withdrawn
Summary last modified: January 24, 2007.
Accessed: May 10, 2009
Available at: www.clinicaltrials.gov/ct2/show/NCT00319332
NCT00078676
NCT00319332
CCBX001-049 A Study of Rituximab Versus Iodine I-131 Tositumomab Therapy for Patients with Non-Hodgkin’s Lymphoma
Outcomes: Response and safety
Projected accrual: 506 patients
Status: Terminated
Summary last modified: November 8, 2005
Accessed: May 10, 2009
Available at: www.clinicaltrials.gov/ct2/show/NCT00078598
NCT00078598
NCT0026898344
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appendix a  UPDATED LITERATURE SEARCH
To ensure that our systematic review and conclusions 
remained valid, we updated the medline literature 
search outlined in Table i to May 10, 2009, from 
2005, with a focus on randomized controlled trials 
and single-arm noncomparative studies. The same 
inclusion criteria that defined the original search 
were again applied. The new literature search iden-
tified 165 citations. Seven full publications met the 
inclusion criteria. No randomized phase iii studies 
were identified for this time period. All of the reports 
were single-arm phase ii reports. One publication, 
an integrated analysis of five pivotal studies on 
131I–tositumomab, had already been included in 
the systematic review 44. Another study provided a 
longer-term update of a published report identified 
in the review 26; three other reports represented the 
final publication of abstracts identified in the re-
view 33,24,30. Thus, only two new single-arm studies 
were discovered 41,42 (see Table a-i). The data from 
the updated reports and the two novel studies do not 
affect the summary answers to the questions that 
guided the original systematic review.47
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